UNSPSC 51285404: Cefoxazole

This classification denotes a cephalosporin antibiotic with the molecular formula C21H18ClN3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) BN10X2TL6I, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetoxy)methyl)-7-(((3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-8-oxo-, (6r-trans)- but more generally known as cefoxazole, which bears US NIH Compound Identifier 65798.

UNSPSC 51285404 Cefoxazole is a Commodity code that nominally identifies a specific antibiotic pharmaceutical product, but recent state and local procurement activity shows little alignment with this particular drug. The two most recent opportunities tagged to this code involve different pharmaceuticals entirely: one concerns antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) procured through a cooperative purchasing piggyback contract, and the other addresses opioid-reversal medication and drug deactivation systems. State and local health agencies and counties appear to be the primary soliciting bodies, though the sparse recent record makes it difficult to characterize a sustained issuing-body pattern. The code shows no evidence of repeated use by a particular jurisdiction or purchasing consortium.

Geographic activity appears limited to Illinois and Florida based on the two available records. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for antibiotic tablet supply under an Invitation for Bid (IFB) process, while Seminole County, Florida released an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems with a July 26, 2023 response deadline. Neither opportunity directly involves Cefoxazole procurement. The code's nominal scope and actual recent procurement activity diverge significantly, suggesting the code may be misapplied in state and local procurement systems or sees minimal use for its intended pharmaceutical product.